Skip to main content
Clinical Trials/NCT00966199
NCT00966199UnknownPhase 4

Medication Induced Blood Pressure Reduction; Assessment of Cerebral Perfusion and Cognition in Hypertensive Elderly

Radboud University Medical Center1 site in 1 country60 target enrollmentStarted: September 2009Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 4
Enrollment
60
Locations
1
Primary Endpoint
Cerebral blood flow

Study Overview

Brief Summary

The purpose of this study is to determine if a reduction in systolic blood pressure induced by anti-hypertensive medication results in changes in cerebral perfusion and cognition in hypertensive elderly. Hypertensive elderly will be treated using open-label anti-hypertensive medication for 8-12 weeks. Changes in cerebral perfusion and cognition will be assessed before and after treatment.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Basic Science
Masking
None

Eligibility Criteria

Ages
70 Years to — (Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age >= 70 years
  • Systolic office blood pressure >= 160 mmHg
  • Systolic home blood pressure >= 155 mmHg

Exclusion Criteria

  • Diabetes Mellitus
  • Atrial fibrillation
  • Renal failure requiring dialysis
  • Life expectancy of less than 1 year
  • Disabling stroke
  • Contraindication for MRI or anti-hypertensive medication
  • Systolic blood pressure > 220 mmHg

Arms & Interventions

Hypertensive elderly

Experimental

community dwelling hypertensive elderly from general practices

Intervention: anti-hypertensive medication (Drug)

Outcomes

Primary Outcomes

Cerebral blood flow

Time Frame: T1, 8-12 weeks of treatment, T2

Secondary Outcomes

  • Cognitive functioning assessed by neuropsychological testing(T1, 8-12 weeks of treatment, T2-3)

Investigators

Sponsor Class
Other

Study Sites (1)

Loading locations...

Similar Trials